Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Cemiplimab + REGN5668|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Cemiplimab||Libtayo||REGN2810|SAR439684||Immune Checkpoint Inhibitor 98 PD-L1/PD-1 antibody 68||Libtayo (cemiplimab) is a human antibody that targets PD-1 (PDCD1) and prevents interaction with PD-L1 (CD274) and PD-L2 (PDCD1LG2), potentially resulting in increased anti-tumor immune response and decreased tumor growth (PMID: 28265006). Libtayo (cemiplimab) is FDA approved for use in patients with cutaneous squamous cell carcinoma, who are not not eligible for curative surgery or radiation, in patients with locally advanced or metastatic basal cell carcinoma who have received or are not eligible for a hedgehog pathway inhibitor, and as first-line treatment in patients with advanced non-small cell lung cancer with high PD-L1 expression (TPS>=50%) and no EGFR, ALK, or ROS1 aberrations (FDA.gov).|
|REGN5668||REGN 5668|REGN-5668||MUC16 Targeted Therapy 7||REGN5668 is a bispecific monoclonal antibody that targets both CD28 and MUC16 (CA125), resulting in cross-linking of CD28-positive T-cells to MUC16-expressing tumor cells, potentially leading to enhanced cytotoxic response against MUC16-positive tumor cells (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04590326||Phase Ib/II||REGN4018 + REGN5668 Cemiplimab + REGN5668||Study of REGN5668 Administered in Combination With Cemiplimab or REGN4018 in Adult Women With Recurrent Ovarian Cancer.||Recruiting||USA||0|